- Global proteomics (Cell, Tissue, blood proteome)
Label-free quantification of peptide/protein
Label-free analysis based on data-independent acquisition (DIA)
Our industry-leading protein analysis of non-depleted plasma can result in 1,300 protein identifications in one-hour per single sample.
Our isotope-labeling enables a sample-to-sample comparison analysis in protein quantiﬁcation.
Bertis labeling quantification and advanced fractionation technology enable industry-leading protein quantification analysis in cell or tissue samples.
Our phospho/glyco proteomics ensures high-quality post-translational modification (PTM) analysis of proteins, providing an optimized solution for biomarker discovery and mechanism of action analysis.
Our bioinformatics analysis provides results specifically tailored to research purposes.
Our bioinformatics analysis provides your research needs from basic analysis of protein composition and quantiﬁcation to in-depth systems biology analysis.
We provide analysis services that meet our customer’s needs through continuous communication and interaction.
- Protein identification and quantification
Report on the qualitative and quantitative information of proteins present in samples
- Differential expression analysis
Identification of proteins with statistically significant differences in expression levels
- Gene ontology analysis
Analysis of cellular mechanisms, molecular functions, and subcellular localization
- Pathway analysis
Interpretation of subcellular mechanisms through biological pathway analysis
- Post-translational modification (PTM) analysis
Phosphorylation and glycosylation analysis at proteomic levels
- Multi-omics integration: DNAs, RNAs, Proteins, Metabolites
Analysis and interpretation of correlation between proteomics and other omics data
- Clustering analysis
- Pathway analysis
- Differential expression analysis
- Companion Diagnostics (CDx)
We provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases.
For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs.
PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology.
Success rates in clinical trials depending on the use of biomarkers (2011-2020)
BIO, Informa Pharma Intelligence, QLS Advisors (2021) Clinical Development Success Rates and Contributing Factors 2011 – 2020
Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.
Cell line & Drug Candidate specific biomarker
- Cell line-dependent biomarker identification
- Identification of molecular subtypes and biomarker discovery on the basis of pan-omic analysis of cell lines
- Efficacy or safety check for each cell line after drug candidate processing: MoA confirmation
Animal model classification and efficacy/safety analysis through a drug specific biomarker
- Subtyping and establishment of biomarkers for each subtype based on the pan-omics data from clinical specimen
- Identification of drug-specific subtypes based on changes in each biomarker after drug candidate processing
- Establish an evidence, such as dosage and dosing period of a drug candidate through biomarker expression
- Exosome Therapeutics Quality Control
Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases.
The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package.
MFDS Guidelines for Extracellular Vesicle Therapeutics
Exosome RNA Sequencing
PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods.
We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years.
PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction.
We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
- Protein Characterization (Physicochemical property of proteins)
Our structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars.
Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities.
Protein identification and quantification
Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes
- Full Length-Amino acids sequencing
Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches)
Improved N- and C-terminal sequencing of proteins
Post-translational modification (PTM)
More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently
Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins
- Glycosylation site determination
- Glycan profiling
- Site-specific glycan identification and quantification
- Glycomics research with glycan enrichment